Drug Type Autologous CAR-T |
Synonyms AntiCD19/AntiCD22 CART cell therapyChongqing Precision Biotech, CD19/CD22 dual CART Chongqing Precision Biotech |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD22 inhibitors(CD22 inhibitors), Gene transference(Gene transference) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | China | 07 Mar 2021 | |
| B-Cell Leukemia | Phase 2 | China | 25 Aug 2020 | |
| B-Cell Lymphoma | Phase 2 | China | 25 Aug 2020 |





